A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
What is the purpose of this trial?
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
- Trial withLoxo Oncology, Inc.
- Start Date04/26/2022
- End Date10/01/2020
- Last Updated04/28/2022
- Study HIC#2000027406